Skip to Main Content

Advertisement

Skip Nav Destination

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”

December 30, 2021
No


Tara L. Lin, MD, shares the initial findings from a trial evaluating venetoclax with standard low-dose cytarabine in older patients with acute myeloid leukemia who are unfit for intensive chemotherapy.

Advertisement

  CURRENT ISSUE
  Mid-January 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X